BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Treatment
26947 results:

  • 1. ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells.
    Wu P; Wang X; Yin M; Zhu W; Chen Z; Zhang Y; Jiang Z; Shi L; Zhu Q
    Int J Nanomedicine; 2024; 19():4465-4493. PubMed ID: 38779103
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Drug screening on digital microfluidics for cancer precision medicine.
    Zhai J; Liu Y; Ji W; Huang X; Wang P; Li Y; Li H; Wong AH; Zhou X; Chen P; Wang L; Yang N; Chen C; Chen H; Mak PI; Deng CX; Martins R; Yang M; Ho TY; Yi S; Yao H; Jia Y
    Nat Commun; 2024 May; 15(1):4363. PubMed ID: 38778087
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. SPONTANEOUS REGRESSION OF HEPATOCELLULAR CARCINOMA: FOCUSING IN THE ASSOCIATED RISK FACTORS.
    Tovo CV; Ribas CR; Sartori GDP; Coral GP; Suwa E; Mattos AA
    Arq Gastroenterol; 2024; 61():e23151. PubMed ID: 38775585
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Epidemiological, Diagnostic and Therapeutic Aspects of Hepatocellular Carcinoma in Morocco: A Case Series and Review of Literature.
    Zouaki I; Aiterrami A; Samlani Z; Oubaha S; Krati K
    Gulf J Oncolog; 2024 May; 1(45):75-90. PubMed ID: 38774936
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
    Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
    Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Hepatocellular carcinoma: Advances in systemic therapies.
    Wu TK; Hui RW; Mak LY; Fung J; Seto WK; Yuen MF
    F1000Res; 2024; 13():104. PubMed ID: 38766497
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A multi-parametric prognostic model based on clinicopathologic features: vessels encapsulating tumor clusters and hepatic plates predict overall survival in hepatocellular carcinoma patients.
    Xiong SP; Wang CH; Zhang MF; Yang X; Yun JP; Liu LL
    J Transl Med; 2024 May; 22(1):472. PubMed ID: 38762511
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
    Wang X; Yang Y
    Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
    Salim N; Tumanova K; Popodko A; Libson E
    JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.
    Ni Q; Jia H; Zhang Y; Lu J; Chang H
    Cancer Med; 2024 May; 13(10):e6952. PubMed ID: 38752672
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
    Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
    Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
    Ooi SL; Micalos PS; Kim J; Pak SC
    Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
    Xiao Y; Deng W; Luo L; Zhu G; Xie J; Liu Y; Wan R; Wen W; Hu Z; Shan R
    BMC Cancer; 2024 May; 24(1):588. PubMed ID: 38745113
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
    Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
    Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
    [No Abstract]    [Full Text] [Related]  

  • 18. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
    Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
    Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
    Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
    JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
    Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
    Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1348.